Analysts at BZW Research believe the market is "significantly undervaluing" the shares of Glaxo Wellcome and recommend purchase of the stock, and analysts at Morgan Stanley are enthusiastic about the group's revenue potential from new products.
Sentiment towards GW's shares remains depressed due to the uncertainties surrounding the future US patent of Zantac (ranitidine), Steve Plag and James Dodwell at BZW point out, as well as concerns that new products will not fill the gap. They say the uncertainty on Zantac is unwarranted given that it is now well out of proportion with the likely impact that a successful defence, or otherwise, of the US patent will have on GW's future earnings and dividends stream.
They estimate that the retention of Zantac patent protection in the USA will alter compound earnings per share growth over the period 1995-2000 by less than 1% (10% vs 9.6% per annum). Furthermore, they say, the maximum absolute differential in earnings is equivalent to just 3.3 pence (in 1998) equating to just over 40 pence in the share price.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze